Treating Viral Infections with mRNA-Encoded Cas13

Regenerative medicine has become a key focus worldwide and the number of stem cell therapy trials are rapidly increasing every year. Yet, large-scale and GMP-compliant stem cell manufacturing is still a major hurdle for clinical applications across the globe. In this webinar, we will show you how to implement GMP-compliant and scalable manufacturing of different adherent cell types, such as pluripotent stem cells and their derivatives, in the CliniMACS Prodigy® Adherent Cell Culture System.

Cure rates for children with cancer have increased dramatically over the past 40 years with the advent of modern treatment strategies, but most patients have serious life-long medical conditions as a result of the toxicity of their treatments. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently described entity that has been associated with chronic diseases, most notably coronary artery disease. To determine if the presence and features of CHIP are different in childhood cancer survivors compared to age and sex-matched controls, we performed targeted single-cell DNA sequencing of thousands of mature and progenitor hematopoietic cells from a cohort of patients that are greater than 50 years of age and received greater than 25g/m2 of highly mutagenic alkylating chemotherapy as a child.

Liquid biopsy, utilizing blood as a less invasive alternative for tissue samples, is becoming more and more prominent in precision medicine. The possibility to analyze blood samples across the species matrix makes mass spectrometry-based proteomics a powerful tool for early-stage, translational, and clinical research.

The COVID-19 pandemic has shown the world that the effectiveness of mRNA vaccine technology is undeniable. The potential for these vaccines to efficiently treat a wide range of communicable diseases is enormous, and the technology is poised to explode into the marketplace. However, effective mRNA vaccines are only as good as the materials and methodologies used to create them, as well as the analytical steps used to test their potency, stability, and clinical efficacy. Traditional analytical methods are slow and end up wasting investigators’ time and money. Advanced imaging and analysis platforms may hold the key to simplifying vaccine development and manufacturing bottlenecks, as they are fast and can be multiplexed to answer multiple scientific questions per analysis.